🇺🇸 FDA
Pipeline program

Pimavanserin 34 mg

ACP-103-032

Phase 2 small_molecule terminated

Quick answer

Pimavanserin 34 mg for Agitation and Aggression in Alzheimer's Disease is a Phase 2 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
ACADIA PHARMACEUTICALS INC
Indication
Agitation and Aggression in Alzheimer's Disease
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials